New biomarker model aims to reduce unnecessary lung biopsies

NCT ID NCT06074133

Ongoing Diagnosis Sponsor: Vanderbilt-Ingram Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a combined biomarker model (CBM) that uses a blood test and CT scan features to better classify lung nodules as benign or cancerous. Researchers will follow 103 adults with intermediate-risk nodules to see if the model can reduce unnecessary invasive procedures and speed up cancer diagnosis. It is an observational pilot study, not a treatment trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a more accurate way to tell if a lung nodule is cancerous, helping patients avoid unnecessary invasive tests.
What could go wrong: This is a small, early pilot study (103 participants) that is only observing outcomes, not testing a treatment. The model may not prove accurate enough in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY NODULE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY NODULE

Contacts and locations

Locations

Rocky Mountain Regional VA Medical Center

Aurora, Colorado, 80045, United States
University of Colorado

Aurora, Colorado, 80045, United States
VA Tennessee Valley Healthcare Center

Nashville, Tennessee, 37212, United States
Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.